Cecchi M, Minervini R, Sepich C A, Ippolito C, Pagni G L, Summonti D, Di Benedetto A, Fiorentini L
Department of Urology, University of Pisa, Italy.
Int Urol Nephrol. 1998;30(5):575-80. doi: 10.1007/BF02550548.
Gleason score has been identified as an important variable to predict disease extent and biologic behaviour of prostate cancer. However, the correlation between Gleason score of needle biopsy and surgical specimen is often poor. We studied 72 patients who underwent needle biopsy and radical prostatectomy to correlate Gleason score with PSA, clinical and pathological tumour stage. Only 47.2% of Gleason scores were identical in the biopsy and specimens, 37.5% were undergraded and 15.2% were overgraded. Correlations between clinical and pathological stage were identical in 30.5% of patients, 61.1% of patients were understaged and 8.3% overstaged. In conclusion, accuracy of clinical staging and grading of prostate cancer is low. Although the Gleason score on needle biopsy might be useful to predict the final stage and grade, correlation with surgical specimen is poor.
Gleason评分已被确定为预测前列腺癌疾病范围和生物学行为的一个重要变量。然而,穿刺活检的Gleason评分与手术标本之间的相关性往往较差。我们研究了72例行穿刺活检和根治性前列腺切除术的患者,以将Gleason评分与前列腺特异性抗原(PSA)、临床和病理肿瘤分期相关联。活检和标本中只有47.2%的Gleason评分相同,37.5%的评分低估,15.2%的评分高估。30.5%的患者临床分期与病理分期相同,61.1%的患者分期低估,8.3%的患者分期高估。总之,前列腺癌临床分期和分级的准确性较低。虽然穿刺活检的Gleason评分可能有助于预测最终分期和分级,但与手术标本的相关性较差。